{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T20:27:08Z","timestamp":1759177628927,"version":"3.37.3"},"reference-count":84,"publisher":"Informa UK Limited","issue":"3","funder":[{"DOI":"10.13039\/100000890","name":"National Multiple Sclerosis Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000890","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Barford and Love MS Fund of St. Michael\u2019s Hospital Foundation"},{"DOI":"10.13039\/501100000261","name":"Multiple Sclerosis Society of Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000261","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Neurodegener. Dis. Manag."],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.2217\/nmt-2021-0005","type":"journal-article","created":{"date-parts":[[2021,5,20]],"date-time":"2021-05-20T08:33:30Z","timestamp":1621499610000},"page":"207-220","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":3,"title":["Ozanimod for the Treatment of Relapsing Forms of Multiple Sclerosis"],"prefix":"10.1080","volume":"11","author":[{"given":"Andrea M","family":"Kuczynski","sequence":"first","affiliation":[{"name":"Department of Medicine Division of Neurology St. Michael\u2019s Hospital University of Toronto\rToronto\rCanada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5519-6088","authenticated-orcid":false,"given":"Jiwon","family":"Oh","sequence":"additional","affiliation":[{"name":"Department of Medicine Division of Neurology St. Michael\u2019s Hospital University of Toronto\rToronto\rCanada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2021,5,20]]},"reference":[{"issue":"4","key":"e_1_3_3_3_1","first-page":"191","article-title":"New biological agents in the treatment of multiple sclerosis","volume":"119","author":"Buc M","year":"2018","unstructured":"Buc M . New biological agents in the treatment of multiple sclerosis. Bratisl. Lek. Listy, 119(4), 191\u2013197 (2018).","journal-title":"Bratisl. Lek. Listy"},{"doi-asserted-by":"publisher","key":"e_1_3_3_4_1","DOI":"10.1155\/2013\/963748"},{"doi-asserted-by":"publisher","key":"e_1_3_3_5_1","DOI":"10.1016\/S0022-510X(02)00191-0"},{"doi-asserted-by":"publisher","key":"e_1_3_3_6_1","DOI":"10.2353\/ajpath.2010.091234"},{"doi-asserted-by":"publisher","key":"e_1_3_3_7_1","DOI":"10.1002\/(SICI)1097-4547(19970215)47:4<384::AID-JNR3>3.0.CO;2-A"},{"doi-asserted-by":"publisher","key":"e_1_3_3_8_1","DOI":"10.1002\/glia.1085"},{"doi-asserted-by":"publisher","key":"e_1_3_3_9_1","DOI":"10.1146\/annurev.biochem.78.072407.103733"},{"doi-asserted-by":"publisher","key":"e_1_3_3_10_1","DOI":"10.1034\/j.1600-065X.2003.00068.x"},{"doi-asserted-by":"publisher","key":"e_1_3_3_11_1","DOI":"10.1007\/s40263-015-0261-z"},{"doi-asserted-by":"publisher","key":"e_1_3_3_12_1","DOI":"10.1046\/j.1460-9568.1998.00117.x"},{"doi-asserted-by":"publisher","key":"e_1_3_3_13_1","DOI":"10.1074\/jbc.275.19.14281"},{"doi-asserted-by":"publisher","key":"e_1_3_3_14_1","DOI":"10.1016\/S0306-4522(02)00791-1"},{"doi-asserted-by":"publisher","key":"e_1_3_3_15_1","DOI":"10.1002\/glia.10297"},{"doi-asserted-by":"publisher","key":"e_1_3_3_16_1","DOI":"10.1002\/(SICI)1096-9861(19980907)398:4<587::AID-CNE10>3.0.CO;2-5"},{"doi-asserted-by":"publisher","key":"e_1_3_3_17_1","DOI":"10.1523\/JNEUROSCI.4645-04.2005"},{"doi-asserted-by":"publisher","key":"e_1_3_3_18_1","DOI":"10.1111\/j.1471-4159.2007.04629.x"},{"doi-asserted-by":"publisher","key":"e_1_3_3_19_1","DOI":"10.1002\/glia.21021"},{"doi-asserted-by":"publisher","key":"e_1_3_3_20_1","DOI":"10.1016\/j.neuropharm.2016.11.006"},{"doi-asserted-by":"publisher","key":"e_1_3_3_21_1","DOI":"10.1016\/S1474-4422(16)00041-7"},{"doi-asserted-by":"publisher","key":"e_1_3_3_22_1","DOI":"10.1096\/fj.06-7420com"},{"doi-asserted-by":"publisher","key":"e_1_3_3_23_1","DOI":"10.1096\/fj.10-173203"},{"doi-asserted-by":"publisher","key":"e_1_3_3_24_1","DOI":"10.1074\/jbc.C200176200"},{"doi-asserted-by":"publisher","key":"e_1_3_3_25_1","DOI":"10.1038\/nrd3248"},{"doi-asserted-by":"publisher","key":"e_1_3_3_26_1","DOI":"10.1056\/NEJMoa052643"},{"doi-asserted-by":"publisher","key":"e_1_3_3_27_1","DOI":"10.1016\/S1474-4422(14)70049-3"},{"doi-asserted-by":"publisher","key":"e_1_3_3_28_1","DOI":"10.1056\/NEJMoa0909494"},{"doi-asserted-by":"publisher","key":"e_1_3_3_29_1","DOI":"10.1056\/NEJMoa0907839"},{"doi-asserted-by":"publisher","key":"e_1_3_3_30_1","DOI":"10.1212\/01.wnl.0000327609.57688.ea"},{"doi-asserted-by":"publisher","key":"e_1_3_3_31_1","DOI":"10.1212\/NXI.0000000000000966"},{"doi-asserted-by":"publisher","key":"e_1_3_3_32_1","DOI":"10.1212\/WNL.0000000000005529"},{"doi-asserted-by":"publisher","key":"e_1_3_3_33_1","DOI":"10.1016\/j.msard.2016.09.010"},{"doi-asserted-by":"publisher","key":"e_1_3_3_34_1","DOI":"10.1007\/s13311-017-0565-4"},{"doi-asserted-by":"publisher","key":"e_1_3_3_35_1","DOI":"10.1007\/s00415-013-7115-8"},{"doi-asserted-by":"publisher","key":"e_1_3_3_36_1","DOI":"10.1212\/NXI.0000000000000874"},{"doi-asserted-by":"publisher","key":"e_1_3_3_37_1","DOI":"10.1001\/jamaneurol.2016.0826"},{"doi-asserted-by":"publisher","key":"e_1_3_3_38_1","DOI":"10.1212\/NXI.0000000000000377"},{"doi-asserted-by":"publisher","key":"e_1_3_3_39_1","DOI":"10.1016\/S1474-4422(16)00018-1"},{"doi-asserted-by":"publisher","key":"e_1_3_3_40_1","DOI":"10.1080\/14656566.2020.1799977"},{"doi-asserted-by":"publisher","key":"e_1_3_3_41_1","DOI":"10.1136\/jnnp-2013-307282"},{"doi-asserted-by":"publisher","key":"e_1_3_3_42_1","DOI":"10.1080\/13543784.2019.1676725"},{"doi-asserted-by":"publisher","key":"e_1_3_3_43_1","DOI":"10.1186\/s12974-016-0686-4"},{"doi-asserted-by":"publisher","key":"e_1_3_3_44_1","DOI":"10.1016\/S0140-6736(18)30475-6"},{"doi-asserted-by":"publisher","key":"e_1_3_3_45_1","DOI":"10.1016\/S1474-4422(13)70102-9"},{"issue":"1","key":"e_1_3_3_46_1","first-page":"P05.153","article-title":"Effect of the sphingosine 1-phosphate receptor agonist ONO-4641 on circulating lymphocytes in patients with relapsing-remitting multiple sclerosis: results from the Phase IIDreaMS trial","volume":"80","author":"Bar-Or A","year":"2013","unstructured":"Bar-Or A , ZippF, KrzystofS, DueB, VollmerT. Effect of the sphingosine 1-phosphate receptor agonist ONO-4641 on circulating lymphocytes in patients with relapsing-remitting multiple sclerosis: results from the Phase IIDreaMS trial. Neurology, 80(Meeting Abstracts 1), P05.153 (2013).","journal-title":"Neurology"},{"doi-asserted-by":"publisher","key":"e_1_3_3_47_1","DOI":"10.1002\/jcph.887"},{"doi-asserted-by":"publisher","key":"e_1_3_3_48_1","DOI":"10.1080\/14656566.2018.1540592"},{"doi-asserted-by":"publisher","key":"e_1_3_3_49_1","DOI":"10.1002\/cpdd.383"},{"doi-asserted-by":"publisher","key":"e_1_3_3_50_1","DOI":"10.1212\/NXI.0000000000000839"},{"unstructured":"ZEPOSIA\u00ae prescribing information. US Food and Drug Administration MA USA (2020).","key":"e_1_3_3_51_1"},{"doi-asserted-by":"publisher","key":"e_1_3_3_52_1","DOI":"10.1177\/1352458513500551"},{"issue":"3","key":"e_1_3_3_53_1","first-page":"118","article-title":"Post-treatment recovery of lymphocyte subsets in healthy volunteers treated with ozanimod. P0228","volume":"26","author":"Harris S","year":"2020","unstructured":"Harris S , TranJQ, ZhangP, SouthworthH. Post-treatment recovery of lymphocyte subsets in healthy volunteers treated with ozanimod. P0228. Mult. Scler. J., 26(S3), 118\u2013659 (2020).","journal-title":"Mult. Scler. J."},{"unstructured":"Harris S TranJQ SouthworthH SpencerCM CreeBAC ZamvilSS. Effect of ozanimod on circulating leukocyte subtypes: data from a randomised open-label Phase I study in patients with relapsing multiple sclerosis. Presented at: ECTRIMS 2019 Stockholm Sweden (2019).","key":"e_1_3_3_54_1"},{"doi-asserted-by":"publisher","key":"e_1_3_3_55_1","DOI":"10.1016\/j.jns.2013.02.011"},{"doi-asserted-by":"publisher","key":"e_1_3_3_56_1","DOI":"10.1111\/bph.12938"},{"issue":"3","key":"e_1_3_3_57_1","first-page":"118","article-title":"Species variation in sphingosine 1-phosphate receptor subtype 5 affects response to ozanimod in preclinical models of multiple sclerosis. P0395","volume":"26","author":"Selkirk J","year":"2020","unstructured":"Selkirk J , YanG, ChingNet al. Species variation in sphingosine 1-phosphate receptor subtype 5 affects response to ozanimod in preclinical models of multiple sclerosis. P0395. Mult. Scler. J., 26(S3), 118\u2013659 (2020).","journal-title":"Mult. Scler. J."},{"doi-asserted-by":"publisher","key":"e_1_3_3_58_1","DOI":"10.3390\/cells9051290"},{"doi-asserted-by":"publisher","key":"e_1_3_3_59_1","DOI":"10.1177\/1352458518789884"},{"doi-asserted-by":"publisher","key":"e_1_3_3_60_1","DOI":"10.1016\/S1474-4422(19)30238-8"},{"doi-asserted-by":"publisher","key":"e_1_3_3_61_1","DOI":"10.1016\/S1474-4422(19)30239-X"},{"unstructured":"Harris S ComiG CreeBACet al. Effect of ozanimod on neurofilament light chain level in relapsing multiple sclerosis: pooled results from Phase II and Phase III trials. Presented at: ECTRIMS 2019 Stockholm Sweden (2019).","key":"e_1_3_3_62_1"},{"unstructured":"Steinman L ComiG Bar-OrAet al. Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: results from the DAYBREAK open-label extension study. Presented at: AAN 2019 Pennsylvania USA (2019).","key":"e_1_3_3_63_1"},{"unstructured":"Jeffery D SchipplingS GassAet al. Effect of ozanimod on quality of life in patients with RMS by baseline thalamic volume quartile: a post hoc exploratory analysis of Phase III RADIANCE. Presented at: ACTRIMS 2019 Florida USA (2020).","key":"e_1_3_3_64_1"},{"doi-asserted-by":"publisher","key":"e_1_3_3_65_1","DOI":"10.1212\/WNL.0000000000007099"},{"unstructured":"DeLuca J HuangD CohenJAet al. Assessment of cognitive processing speed in the Phase III SUNBEAM trial demonstrates sustained improvement in ozanimod-treated patients. Presented at: ACTRIMS 2019 Texas USA (2019).","key":"e_1_3_3_66_1"},{"doi-asserted-by":"publisher","key":"e_1_3_3_67_1","DOI":"10.1016\/j.msard.2020.102673"},{"unstructured":"Schippling S DeLucaJ SilvaDet al. Effect of ozanimod on the relationship between changes in cognition and grey matter volume in RMS: a post hoc exploratory analysis of the Phase III SUNBEAM trial. Presented at: ECTRIMS 2019 Stockholm Sweden (2019).","key":"e_1_3_3_68_1"},{"doi-asserted-by":"publisher","key":"e_1_3_3_69_1","DOI":"10.1016\/j.jns.2017.11.028"},{"unstructured":"Selmaj KW SteinmanL ComiGet al. Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis in DAYBREAK: an open-label extension study of ozanimod Phase 1\u22123 trials. (Abstract P0217) Presented at: MS Virtual 2020 (2020).","key":"e_1_3_3_70_1"},{"doi-asserted-by":"crossref","unstructured":"Hartung H-P CreeBAC SelmajKWet al. Low rate of infections with long-term use of ozanimod in relapsing multiple sclerosis trials(1596). (abstract) Presented at: AAN 2020 (2020).","key":"e_1_3_3_71_1","DOI":"10.1212\/WNL.94.15_supplement.1596"},{"unstructured":"Minton N HenryA JanjuaA PoliGR. Pregnancy outcomes in the ozanimod multiple sclerosis clinical development program. (abstract) Presented at: AAN 2020 (2020).","key":"e_1_3_3_72_1"},{"doi-asserted-by":"publisher","key":"e_1_3_3_73_1","DOI":"10.1212\/WNL.0000000000000137"},{"doi-asserted-by":"publisher","key":"e_1_3_3_74_1","DOI":"10.2217\/cer-2019-0169"},{"doi-asserted-by":"publisher","key":"e_1_3_3_75_1","DOI":"10.1111\/ane.12881"},{"doi-asserted-by":"publisher","key":"e_1_3_3_76_1","DOI":"10.1007\/s13167-019-00192-z"},{"doi-asserted-by":"publisher","key":"e_1_3_3_77_1","DOI":"10.1212\/NXI.0000000000000783"},{"doi-asserted-by":"publisher","key":"e_1_3_3_78_1","DOI":"10.1002\/ana.26028"},{"doi-asserted-by":"publisher","key":"e_1_3_3_79_1","DOI":"10.1001\/jamaneurol.2020.2581"},{"doi-asserted-by":"publisher","key":"e_1_3_3_80_1","DOI":"10.1212\/NXI.0000000000000753"},{"doi-asserted-by":"publisher","key":"e_1_3_3_81_1","DOI":"10.1212\/WNL.46.4.907"},{"doi-asserted-by":"publisher","key":"e_1_3_3_82_1","DOI":"10.1212\/WNL.0000000000000560"},{"doi-asserted-by":"publisher","key":"e_1_3_3_83_1","DOI":"10.1212\/NXI.0000000000000279"},{"doi-asserted-by":"publisher","key":"e_1_3_3_84_1","DOI":"10.1016\/j.ncl.2017.08.007"},{"unstructured":"Cohan S KumarJ ArndorferS ZhuX ZivkovicM TencerT. Comparative efficacy and safety of ozanimod versus teriflunomide for relapsing-remitting multiple sclerosis: a matching-adjusted indirect comparison. Abstract P0047 Presented at: MSVirtual 2020: 8th Joint ACTRIMS-ECTRIMS Meeting11\u201313 September 2020.","key":"e_1_3_3_85_1"},{"doi-asserted-by":"publisher","key":"e_1_3_3_86_1","DOI":"10.1007\/s40263-021-00805-0"}],"container-title":["Neurodegenerative Disease Management"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/nmt-2021-0005","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,23]],"date-time":"2024-05-23T19:48:51Z","timestamp":1716493731000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/nmt-2021-0005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,20]]},"references-count":84,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["10.2217\/nmt-2021-0005"],"URL":"https:\/\/doi.org\/10.2217\/nmt-2021-0005","relation":{},"ISSN":["1758-2024","1758-2032"],"issn-type":[{"type":"print","value":"1758-2024"},{"type":"electronic","value":"1758-2032"}],"subject":[],"published":{"date-parts":[[2021,5,20]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=inmt20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=inmt20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2021-01-15","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-04-30","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-05-20","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}